Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 11/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.31 |
| ▸ | NNMT | P40261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21646374 | 0.80 | MAP4K4 (0.37) | FYNMAP4K4HCAR3 | |
| SCHEMBL24783510 | 0.80 | ADRA2A (0.37) | FYNMAP4K4EGLN2HCAR3 | |
| SCHEMBL6619928 | 0.74 | MKNK1 (0.47) | FYNMKNK1 | |
| SCHEMBL10490728 | 0.73 | DYRK1A (0.40) | FYNEGLN2 | |
| SCHEMBL6617917 | 0.71 | KDM4E (0.34) | MKNK1 | |
| SCHEMBL6619537 | 0.70 | FYN (0.45) | FYNMKNK1 | |
| SCHEMBL434468 | 0.69 | KDM4E (0.41) | EGLN2 | |
| SCHEMBL10490611 | 0.69 | DYRK3 (0.37) | EGLN2 | |
| SCHEMBL23034388 | 0.69 | HTT (0.31) | EGLN2 | |
| SCHEMBL3894870 | 0.69 | HTT (0.53) | FYNMKNK1NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | FYN 286/4885MKNK1 641/4885MAP4K4 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.